Product Description
Tolbutamide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Tolbutamide is in a class of medications called sulfonylureas. (Sourced from: https://medlineplus.gov/druginfo/meds/a682481.html)
Mechanisms of Action: Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | India | Ireland | Italy | Malaysia | Netherlands | New Zealand | Pakistan | Portugal | Singapore | Slovenia | South Africa | Sri Lanka | Taiwan | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B7981069 | P1 |
Completed |
Healthy Volunteers |
2022-01-10 |